Aberrant activation of the Ras/Raf/MAPK/ERK kinase/extracellular signal-regulated kinase cascade and the VEGF pathway are commonly observed in breast cancer cells leading to malignant cell ...

MAP2K1 mutations have been functionally classified into three groups according to their dependency on upstream RAS/RAF signaling. However, the clinical efficacy of mitogen-activated protein kinase ...

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK ...

Avutometinib is an oral RAF/MEK clamp that potentially inhibits ... complete and durable anti-tumor response through maximal RAS/MAPK pathway inhibition. In contrast to currently available MEK ...

Patients with rapidly accelerated fibrosarcoma (RAF), kirsten rat sarcoma (KRAS), neuroblastoma RAS (NRAS ... continuous MAPK signalling they need by strongly inhibiting the pathway twice ...

2006;2(4):180-181. The fact that PTC is associated with mutually exclusive alterations to MAPK pathway effectors offers intriguing therapeutic opportunities. Ras, RET and B-Raf are part of a ...

Spatiotemporal network dynamics govern cell fate decisions. We use the extracellular signal-regulated kinase (ERK) pathway as a paradigm to describe how temporal activation kinetics and spatial ...

"With the addition of VS-7375, a potential best-in-class oral KRAS G12D (ON/OFF) inhibitor, we are well-positioned to further establish our leadership in targeting RAS/MAPK pathway-driven cancers ...

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced its 2025 priorities and ...

"With the addition of VS-7375, a potential best-in-class oral KRAS G12D (ON/OFF) inhibitor, we are well-positioned to further establish our leadership in targeting RAS/MAPK ... pathway and granted ...